Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
AIMS: Co-primary objectives were to evaluate dalcetrapib (JTT-705/RO4607381), which targets cholesteryl ester transfer protein (CETP), effects on high-density lipoprotein cholesterol (HDL-C) in participants with coronary heart disease or risk equivalents and to evaluate potential changes in mesenteric lymph nodes. METHODS AND RESULTS: Double-blind trial with participants randomized (2:1) to dalcetrapib 900 mg/day (higher than 600 mg phase III dose) or placebo, both with atorvastatin, for 24 weeks (n = 135; one without post-baseline efficacy data was excluded from intent-to-treat population); a subset continued for 24-week extension (n = 77). Lipid changes and safety parameters were assessed. Mesenteric lymph nodes were evaluated by magnetic resonance imaging. Dalcetrapib increased HDL-C (33.4%, Week 24; 33.8%, Week 48), decreased CETP activity (-53.5%, Week 24; -56.5%, Week 48), and increased apolipoprotein A-I (11.4%, Week 24; 16.4%, Week 48). Dalcetrapib showed no clinically relevant differences vs. placebo in adverse events, laboratory parameters including aldosterone, electrocardiograms, and vital signs including blood pressure (BP). Dalcetrapib had no measurable, clinically relevant effect on lymph node size. CONCLUSION: Dalcetrapib 900 mg administered for up to 48 weeks showed no clinically relevant changes in lymph nodes, BP, or other safety parameters. Dalcetrapib effectively increased HDL-C over 48 weeks of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468 · cited 1×
“6 However, current HDL-C-raising therapies have either limited efficacy or tolerability issues.(7) One potential strategy towards raising HDL-C is through inhibition of cholesteryl ester transfer protein (CETP).”
BackgroundGoldenberg, I., Goldbourt, U., Boyko, V., Behar, S., & Reicher-Reiss, H. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.09.078 · Cited by 41
Cited by
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749
Fayad, Z. A., Mani, V., Woodward, M., Kallend, D., Abt, M., Burgess, T., Fuster, V., Ballantyne, C. M., Stein, E. A., Tardif, J.-C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61383-4 · Cited by 538
Self-citationAli, K. M., Wonnerth, A., Huber, K., & Wojta, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02081.x · Cited by 292
Mechanisms and the Evidence Hierarchy
Clarke, B., Gillies, D., Illari, P., Russo, F., & Williamson, J. (2014) · Topoi · doi:10.1007/s11245-013-9220-9 · Cited by 253
“Trials showed, first, that it was effective in increasing serum HDL concentrations in study populations (Stein et al. 2010).”
Metadata
- Authors
- Stein, E. A., Roth, E. M., Rhyne, J. M., Burgess, T., Kallend, D., & Robinson, J. G.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-01-22
- Volume
- 31
- Issue
- 4
- Pages
- 480-488
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2058536244
- Cited by
- 109
- References
- 3
- FWCI
- 26.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. https://app.cochat.ai/papers/10.1093/eurheartj/ehp601
- The paper
- Stein, E. A., Roth, E. M., Rhyne, J. M., Burgess, T., Kallend, D., & Robinson, J. G. (2010). Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. European Heart Journal. https://doi.org/10.1093/eurheartj/ehp601
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.